Gilmanov et al Perceval S 137 Eligible for 10% 77y Retrospective initial single centre experience (2013)() isolated AVR by Update with 175 patients later presented at a conference() right anterior No information provided regarding funding and conflicts of interest minithoracotomy Kocher et al Intuity 152 AS or 7.9% 76y Part of TRITON trial (2013)() Disclosure: Edwards Lifesciences funded the study and managed collection and monitoring of data Martens et al 3f Enable 140 AS, NR 76y European Multicentre Enable trial (2011)() insufficiency or Disclosure: Financial support provided by ATS Medical Mazine et al Perceval S 123 SSAS NR 79y (2013)() Santarpino et al Perceval S 83 Severe calcified 10.7% 77y Part of CAVALIER trial (2012)() AS No information provided regarding funding and conflicts of interest; financial relationship with Sorin for two of the authors disclosed in another paper (Pfeiffer and Fischlein) Shrestha et al Perceval S 180 SSAS 13% 81y Perceval Pivotal trial (2011)() Publication in Abstract form No information provided regarding funding and conflicts of interest Zannis et al Perceval S 140 9.7% 79y Single centre experience likely part of the Perceval Pivotal trial and/or CAVALIER, with at
Gilmanov et al (2013)() Perceval S 137 Eligible for isolated AVR by right anterior minithoracotomy 10% 77y Retrospective initial single centre experience Update with 175 patients later presented at a conference() No information provided regarding funding and conflicts of interest Kocher et al (2013)() Intuity 152 AS or 7.9% 76y Part of TRITON trial Disclosure: Edwards Lifesciences funded the study and managed collection and monitoring of data Martens et al (2011)() 3f Enable 140 AS, or insufficiency NR 76y European Multicentre Enable trial Disclosure: Financial support provided by ATS Medical Mazine et al (2013)() Perceval S 123 SSAS NR 79y Santarpino et al (2012)() Perceval S 83 Severe calcified AS 10.7% 77y Part of CAVALIER trial No information provided regarding funding and conflicts of interest; financial relationship with Sorin for two of the authors disclosed in another paper (Pfeiffer and Fischlein) Shrestha et al (2011)() Perceval S 180 SSAS 13% 81y Perceval Pivotal trial Publication in Abstract form No information provided regarding funding and conflicts of interest Zannis et al Perceval S 140 9.7% 79y Single centre experience likely part of the Perceval Pivotal trial and/or CAVALIER, with at